Tivozanib is primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It functions as a tyrosine kinase inhibitor, specifically targeting vascular endothelial growth factor receptors (VEGFRs). By blocking these receptors, Tivozanib inhibits the growth of new blood vessels that supply tumors, effectively slowing down cancer progression. Its application is particularly beneficial for patients who have not responded well to other treatments, offering an alternative therapeutic option. The drug is administered orally, making it convenient for long-term use in managing the disease. Clinical trials have demonstrated its efficacy in improving progression-free survival in patients with advanced RCC, making it a valuable addition to the arsenal of cancer therapies.